Leading Radiology Benefit Manager Recommends Positive Coverage for AI-QCT, Expanding Access to Advanced Cardiac Imaging Technology
July 15, 2025 (DENVER, CO) – Cleerly, the leader in AI-based advanced cardiovascular imaging, today announced that EviCore, a leading radiology benefit manager providing coverage guidelines to commercial health insurers, has released updated guidelines with positive coverage recommendations for AI-guided quantitative coronary CT angiography (AI-QCT), including Cleerly LABS Plaque Analysis. The updated coverage guidelines become effective October 1, 2025.
EviCore's recommended patient selection criteria align with those established in the Medicare Local Coverage Determinations (LCDs) and include:
This milestone follows Cleerly's efforts to petition Medicare coverage for AI-QCT products. The positive coverage from Medicare, and now EviCore, represents a significant step forward in making advanced cardiac imaging technology accessible to more patients. Commercial health insurers will make individual decisions on guideline adoption and implementation timing based on EviCore's updated recommendations.
Cleerly LABS’ Plaque Analysis is the only AI-based plaque tool that has published data comparing the tool to multiple industry leading invasive imaging modalities, including intravascular ultrasound (IVUS) with a .96 AUC1,2, near-infrared spectroscopy (NIRS) with a .97 AUC1, and optical coherence tomography (OCT) with data to be published this year. Cleerly's Plaque Analysis was validated against Level III readers, and an extensive list of post-market published clinical data can be found on Cleerlyhealth.com.
"This update from EviCore is a pivotal moment in advancing precision coronary care," said James K. Min, MD, founder and CEO of Cleerly. "By including Cleerly LABS Plaque Analysis in their coverage guidelines, EviCore is helping to ensure that patients and physicians have access to the most advanced, clinically tested AI-powered tools for coronary plaque assessment. This will enable more personalized, precise care decisions for patients with coronary artery disease."
The inclusion of Cleerly LABS Plaque Analysis in EviCore's guidelines underscores the growing recognition of AI-powered cardiac imaging as a critical component of modern cardiovascular care. By providing detailed, quantitative analysis of coronary plaque composition and burden, Cleerly's technology enables clinicians to make more informed treatment decisions and deliver personalized care to patients with suspected or known coronary artery disease.
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
Christy Sievert
press@cleerlyhealth.com
